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Background: Alterations in bone mineral density (BMD) in patients with psychotic disorder may reﬂect the
effect of treatment (disease effect observed in patients but not their siblings) or, as an intermediate marker
of cumulative endogenous estrogen exposure, alterations in the neuroprotective effect of estrogen in the
brain (vulnerability effect observed in patients and siblings).
Methods: Dual X-ray absorptiometry (DEXA) scans were acquired in 62 patients with a psychotic disorder, 67
non-psychotic siblings of patients with a psychotic disorder, and 48 controls. BMD (g/cm2), Z-scores and
T-scores were measured in the lumbar spine and proximal femur. Associations between group and BMD
were investigated with multilevel random regression analyses. Group×sex interactions and effects of anti-
psychotic medication (AP) on BMD were examined.
Results: Group was not associated with BMD outcome measures, although patients had consistently lower
BMD measures compared to both siblings and controls. There were no signiﬁcant group×sex interactions,
but stratiﬁed analyses showed that BMD measures in female patients were signiﬁcantly lower in comparison
to female controls and siblings (e.g. total femoral BMD, P vs. C: B=−0.100, p=0.010; P vs. S: B=−0.104,
p=0.008). After excluding female patients who used prolactin-raising AP, the effect was attenuated (e.g. total
femoral BMD, P vs. C: B=−0.073, p=0.072; P vs. S: B=−0.085, p=0.051). In men, there were no signiﬁcant
BMD differences between patients and controls.
Conclusion: Familial risk of psychotic disorder was not associated with BMD. Instead, decreased BMD in the
femur may reﬂect treatment effects or non-familial risk associated with low cumulative endogenous estrogen
levels in women.© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
In the past decade, an increased awareness of compromised
skeletal status in patients with psychotic disorder has developed.
This is based on ﬁndings of reduced bone mineral density (BMD) in
this population, possibly resulting from a high prevalence of risk
factors for osteoporosis (Haddad and Wieck, 2004; Halbreich, 2007).
Some risk factors for osteoporosis may be inherent to positive and
negative symptomatology such as polydipsia (Delva et al., 1989),
diminished dietary intake, decreased physical activity and reduced
sunlight exposure. In addition, comorbid substance abuse may further
inﬂuence vulnerability for osteoporosis, as alcohol and cannabis have
been shown to affect bone metabolism (Bab et al., 2009; Maurel et al.,hology, Maastricht University
The Netherlands. Tel.: +31
(M. Marcelis).
vier OA license.2012). Hyperprolactinemia-induced hypogonadism, secondary to
treatment with potent dopamine-2 receptor antagonists, has also
been proposed as a factor contributing to loss of bone mass in schizo-
phrenia (Bilici et al., 2002; Abraham et al., 2003a; Meaney et al., 2004;
Meaney and O'Keane, 2007; Kishimoto et al., 2008). Notably, not all
studies have found evidence for BMD reduction in patients (Howes
et al., 2005), or for an effect of prolactin-raising antipsychotic drugs
(AP) on BMD (Lee et al., 2010; Renn et al., 2010).
While there is evidence for decreased BMD speciﬁcally in male
patients with schizophrenia (Hummer et al., 2005; Lehman and
Meyer, 2005; Meyer and Lehman, 2006; Kishimoto et al., 2008),
there are also studies suggesting that female patients are particularly
vulnerable to compromised skeletal status (Partti et al., 2010), with
some evidence for higher bone turnover, but normal bone mineral
density (Abraham et al., 2003b; Bergemann et al., 2008).
The above mentioned studies (all cross-sectional, with the excep-
tion of two (Abraham et al., 2003b; Meaney and O'Keane, 2007)), dif-
fer with respect to cohort characteristics (e.g. sample size, stage of
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pausal phase) and correction for confounding factors, which may
have contributed to an inconsistent pattern of results. Nevertheless,
most studies are suggestive of reduced BMD in schizophrenia.
Loss of BMDmay be a consequence of psychotic disorder or its treat-
ment, but an alternative hypothesis is that a reduction in BMD, as a
marker of cumulative endogenous estrogen exposure (Clemons and
Goss, 2001), is an indicator of risk for and development of psychotic dis-
order (due to diminished neuroprotection of estrogen in the brain)
(Maric et al., 2005). A primary low endogenous estrogen level may be
associated with genetic risk of the disorder (intermediate phenotype)
or, alternatively, represent a non-familial marker of risk.
The aimof the present studywas to examine BMD in subjects at high
genetic risk of psychotic disorder (patientswith psychotic disorder) and
subjects at higher than average genetic risk (unaffected siblings of
patients with psychotic disorder) in comparison with individuals at av-
erage genetic risk of psychotic disorder (healthy controls). We hypoth-
esized that BMD, as a marker of cumulative endogenous estrogen
exposure, would be reduced in both patients and siblings, reﬂecting
shared familial liability. The objective was not to identify a large, clini-
cally relevant decline in BMD (e.g. to be able to pinpoint and reduce
fracture risk), but to discern a difference, even small, thatmay be related
to the (familial) etiology of schizophrenia and other psychotic disorders.
2. Materials and methods
2.1. Subjects
Data was collected in the context of an ongoing longitudinal study
in Maastricht, The Netherlands (Habets et al., 2011; Korver et al.,
2012). In selected representative geographic areas in The Netherlands
and Belgium, patients presenting consecutively at mental health ser-
vices either as outpatients or inpatients were recruited for the study.
Siblings were sampled through participating patients. Control sub-
jects were recruited from the same population as the cases using
randommailings in nearby municipalities and through advertisement
in newspapers. Patients between the ages of 16 and 50 years with a
diagnosis of non-organic, non-affective psychosis were included. Suf-
ﬁcient command of the Dutch language was an additional criterion
for inclusion. Diagnosis was based on DSM-IV criteria (APA, 2000),
assessed with the Comprehensive Assessment of Symptoms and His-
tory (CASH) interview (Andreasen et al., 1992). The CASH was also
used to conﬁrm the absence of a diagnosis of non-affective psychosis
in the siblings, and absence of a diagnosis of any psychotic disorder in
the control subjects. For the control subjects, the occurrence of any
psychotic disorder in either the subject or any ﬁrst-degree family
member, assessed using the Family Interview for Genetic Studies,
constituted an exclusion criterion.
The sample consisted of 62 patients with a psychotic disorder (of
whom 50 patients had a diagnosis of schizophrenia, 4 patients had a
diagnosis of schizoaffective disorder, 7 patients had a diagnosis of
psychotic disorder not otherwise speciﬁed and 1 patient had a diag-
nosis of brief psychotic disorder), 67 non-psychotic siblings and 48
controls. The sample included 36 families, of which 24 families con-
tributed one patient and one sibling and two families contributed
one patient and 2 siblings. One family contributed two patients and
one sibling; in one family one patient and 3 siblings participated. Two
families contributed two siblings but no patients. In the control group,
six families contributed two siblings. Thirty-three independent patients,
31 independent siblings, and 36 independent controls participated.
Nine controls and sixteen siblings had a history of major depres-
sive disorder (MDD). In addition, one sibling was diagnosed with dys-
thymic disorder and one with mood disorder due to a general medical
condition.
Prior to DEXA acquisition, participants were screened for the
following exclusion criteria: 1) metabolic or endocrinologic disease,2) dietary deﬁciency or eating disorder, 3) medication use: corticoste-
roids, thyroxin, anti-epileptics, heparin, lithium, cytostatic agents,
4) (semi-)professional athletes, 5) polydipsia (>3 l/day), 6) pregnancy,
and 7) hormonal (infertility) treatment.
2.2. Measures
2.2.1. Substance use
Substance use was assessed using the Composite International
Diagnostic Interview (CIDI) (WHO, 1990). Cannabis use was assessed
as reported lifetime frequency of use. Other drug use, such as stimu-
lants, sedatives, opiates, cocaine, PCP, psychedelics, inhalants or other
(e.g. ecstasy, poppers) was assessed in the same way. Alcohol use was
deﬁned as the average number of weekly instances of consumption
during the previous 12 months. Tobacco usewas deﬁned as the number
of cigarettes, cigars or pipes per day, or number of daily occasions of use
of chewing tobacco or snuff.
2.2.2. Physical activity and sunlight exposure
Physical activity and sunlight exposure were expressed in total
minutes per week.
To quantify physical activity, the total amount of time spent on com-
muting by foot or bicycle, physical activity at work or school, household
chores, active hobbies and sports was summed. Sunlight exposure was
calculated by multiplying the number of days per week a person went
outside by the average number of minutes spent outside on those days.
2.2.3. AP use
Current AP use was classiﬁed by AP type: “prolactin-raising”,
i.e. ﬁrst-generation APs, risperidone and amisulpride; or “prolactin-
sparing”, i.e. second or third-generation APs with the exception of
risperidone and amisulpride.
2.2.4. Use of contraceptive drugs (cumulative exogenous
estrogen exposure)
Cumulative exogenous estrogen exposure in women was deter-
mined by multiplying the daily dose with the total days of use,
expressed in micrograms.
2.2.5. Age at menarche and dysmenorrhea
Age at menarche and the occurrence of menstrual irregularity
were assessed in women. Dysmenorrhea was deﬁned as altered dura-
tion and/or frequency of menses or the absence of two or more
menses during the previous three months. Amenorrhea was deﬁned
as the absence of menses for at least three months.
2.2.6. Familial osteoporosis
The occurrence of familial osteoporosis was documented.
2.3. DEXA acquisition and processing
DEXA scans were acquired at the Maastricht University Medical
Center with a Hologic Discovery A (Tromp Medical, Castricum, The
Netherlands) (NHANES and Ethnic Reference Data). DEXA scans of
two anatomical areas were performed: the lumbar spine, vertebrae
L2 through L4; and the proximal left femur, speciﬁcally the collum,
trochanter major, intertrochanteric area and Ward's triangle. BMD
was expressed in grams per square centimeter (g/cm2), Z-scores
and T-scores. The Z-score compares an individual's BMD with the
mean BMD of a comparable population (with respect to gender, age
and ethnicity). The T-score compares an individual's BMD to peak
bone mass (PBM). Peak bone mass is the highest BMD an individual
is expected to acquire during life. The T-score is used to diagnose
osteopenia and osteoporosis. TheWorld Health Organization employs
the following criteria: T-scores in osteopenia lie between −1.0 and
−2.5; T-scores in osteoporosis are equal or less than −2.5.
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subjects provided written informed consent in accordance with the
committee's guidelines.
2.4. Statistical analyses
Group differences in total BMD, Z-scores and T-scores were ana-
lyzed separately for the lumbar spine and proximal femur. Multilevel
random regression models were ﬁtted (Goldstein, 1987) given hier-
archical clustering occasioned by the fact that participants were clus-
tered in families, compromising statistical independence of the
observations. This was done using the XTREG command in STATA
(STATA Corp., version 11). BMD measures were the dependent vari-
ables in the analyses and group (entered both as linear and dummy
variables (controls = 0, siblings= 1 and patients = 2)) was the inde-
pendent variable. Analyses were adjusted for a priori hypothesized
confounders: cumulative exogenous estrogen exposure, gender, age,
BMI, physical activity, sunlight exposure, tobacco and alcohol use,
and lifetime exposure to cannabis.
To test whether BMDmeasures were not only conditional on group
but also on sex, group×sex interactions were examined. In addition, a
priori stratiﬁed analyses for males and females were conducted sepa-
rately, given strong physiological sex differences in bone metabolism,
possibly violating assumptions of underlying homogeneity in mecha-
nisms and associations. Group×sex interaction terms were evaluated
by Wald test (Clayton and Hills, 1993). In the analyses stratiﬁed by
sex, age at menarche and menstrual irregularity were additional covar-
iates in the model of women.
The study population included nine control subjects and eighteen
siblings with a history of affective disorder. Conceptually, these indi-
viduals may be at risk of decreased BMD due to factors also associated
with psychotic disorder, such as inactivity and diminished sunlight
exposure. In addition, selective serotonin reuptake inhibitors (SSRIs)
potentially reduce BMD (Halbreich, 2007). Therefore, planned sensi-
tivity analyses were conducted excluding these individuals.
Main effects of current type of AP exposure on BMD in patientswere
examined by comparing prolactin-sparing and prolactin-raising APs to
no AP (dummy variable: no AP = 0, prolactin-raising = 1,
prolactin-sparing = 2) using multiple regression procedures; with
sex, age and BMI as potential confounders. Planned sensitivity analyses
were performed excluding patients who used a prolactin-raising AP.
To control for a type I error, all signiﬁcant p-values were subjected
to correction for multiple testing using the Simes method (Simes,
1986; Rodland, 2006). The Simes method avoids overcorrection asso-
ciated with the Bonferroni correction in case the statistical tests are
not independent, as was the case in the present study (BMDmeasuresTable 1
Demographics.
Controls n=48
Sex (n), M/F 13/35
Age at scan 31.17±11.43
Body mass index (BMI) (kg per m2) 24.31±4.34
Age at menarche (years) 13.14±1.56
Dysmenorrhea (n) 6
Lifetime exogenous estrogen exposure (μg) 41 140±44 105
Smoking (cigarettes per day) 1.98±5.42
Alcohol consumption (units per week) 5.50±7.62
Cannabis use (number of times lifetime) 8.87±23.32
Other drug use (number of times lifetime) 0.28±1.17
Activity (minutes per week) 1975±1112
Sunlight exposure (minutes per week) 1270±930
Familial cases of osteoporosis (n) 3
Current AP use (n, patients) –
PRL-raising/PRL-sparing (n)
Means±SDs are reported.
AP: antipsychotic medication; PRL: prolactin.are correlated with each other). p-Values were ranked and Simes
p-values were calculated as j∗alpha/k, where k is the number of
p-values in the ranking and j is the ranking of that p-value. The




There were more female participants in the control group and more
males in the patient group. Controls were slightly older than patients
and siblings. Patients used more tobacco, as well as more cannabis
and other drugs, compared to controls and siblings. Siblings used
more cannabis than controls. Among women, patients experienced
more menstrual irregularities than siblings and controls (Table 1).
Out of 62 patients, 56 currently used AP medication, of whom 28
were prescribed prolactin-raising agents (3 patients used haloperidol,
1 zuclopenthixol, 17 risperidone and 7 amisulpride; of the latter 1
patient used a combination of amisulpride and aripiprazole, 1 used a
combination of amisulpride and haloperidol and 1 patient used a
combination of amisulpride and risperidone). Several patients used
psychotropicmedication other than anAP: twelve used antidepressants
(of which 11 used a SSRI or serotonin and noradrenalin reuptake inhib-
itor (SNRI), and 1 used trazodone), three used benzodiazepines, two
used anticholinergic agents, and there was one occasion of stimulant
(methylphenidate) use. Two control subjects used an SSRI. None of
the siblings used psychotropic medication.
3.2. Mean BMD measures and prevalence of osteopenia/osteoporosis
The raw data showed that mean BMD measures in patients were
lower than those in siblings and controls. Siblings had consistently
lower mean BMD measures than controls in the lumbar spine, but
not the femur. Compared to controls, the proportion of osteopenia
and osteoporosis cases in the group of patients and siblings was larger,
albeit not statistically signiﬁcant (Table 2).
3.3. Associations between group and BMD measures of the lumbar spine
and femur
There was no statistically signiﬁcant association between group
(linear trend) and BMD, although effect sizes were negative for all six
BMD measures. In the patient–control comparison, the direction of
the effect size was consistently negative for all six BMD measures of

















Mean BMD measures and point prevalence of osteopenia and osteoporosis.
Controls Siblings Patients
Total Male Female Total Male Female Total Male Female
Lumbar spine
BMD (g/cm2) 1.076 (0.14) 1.051 (0.15) 1.085 (0.13) 1.072 (0.12) 1.074 (0.13) 1.069 (0.11) 1.046 (0.13) 1.051 (0.14) 1.033 (0.10)
Z-score 0.156 (1.29) −0.400 (1.36) 0.363 (1.22) −0.133 (1.12) −0.291 (1.19) 0.034 (1.04) −0.474 (1.23) −0.561 (1.31) −0.225 (0.99)
T-score −0.081 (1.25) −0.569 (1.32) 0.100 (1.19) −0.202 (1.12) −0.341 (1.19) −0.053 (1.03) −0.527 (1.22) −0.583 (1.30) −0.369 (0.95)
Osteopenia (n) 9 4 5 15 9 6 19a 15 4
Osteoporosis (n) 1 1 0 1 1 0 2 2 0
Femur
BMD (g/cm2) 0.988 (0.12) 1.042 (0.10) 0.967 (0.12) 1.017 (0.15) 1.064 (0.15) 0.967 (0.12) 0.987 (0.15) 1.004 (0.16) 0.937 (0.11)
Z-score 0.238 (0.90) 0.115 (0.70) 0.283 (0.97) 0.180 (1.04) 0.235 (1.11) 0.122 (0.98) −0.144 (1.04) −0.170 (1.06) −0.069 (1.03)
T-score 0.081 (0.93) −0.092 (0.75) 0.146 (0.99) 0.094 (1.05) 0.126 (1.11) 0.059 (1.00) −0.206 (1.05) −0.235 (1.07) −0.125 (1.02)
Osteopenia (n) 6 2 4 9 4 5 15b 11 4
Osteoporosis (n) 0 0 0 0 0 0 0 0 0
Means±SDs are reported.
a One-sided Fisher's exact test (patients vs. controls): 0.115.
b One-sided Fisher's exact test (patients vs. controls): 0.095.
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Comparing patients to siblings, there was a negative association for all
BMD measures. The reduction in total BMD and Z-score of the femur
was signiﬁcant (B=−0.061, 95% CI:−0.117 to−0.005, p=0.033; and
B=−0.414, 95% CI:−0.827 to−0.001, p=0.050 respectively), though
not after Simes correction. The reduction of the femoral T-score did not
reach signiﬁcance (B=−0.384, 95% CI: −0.797 to 0.030, p=0.069)
(Table 3).
3.4. Group×sex interaction and stratiﬁed analyses by sex
There were no signiﬁcant group×sex interactions for the lumbar
spine or proximal femur.
In women, all BMD measures of the femur were signiﬁcantly re-
duced in patients compared to controls and siblings, with no signiﬁ-
cant differences between siblings and controls. These ﬁndings held
after Simes correction (pSimes: pb0.017).
In men, no signiﬁcant associations were found between BMD and
group. The direction of the effect was generally positive in the lumbar
spine, but consistently negative in the femur in male patients and sib-
lings compared to controls (Table 4).
3.5. Associations between antipsychotic medication and BMD
In the total patient group, no signiﬁcant associations between the type
of current AP and BMD were found, when compared to AP-free patients.
In women, but not in men, the current use of a prolactin-raising AP
(n=6) appeared to be negatively associated with BMD measures of the
lumbar spine, when compared to AP-free female patients (n=3) (totalTable 3
Associations between increased genetic risk of psychotic disorder (group) and BMD.
Linear trend S vs. C
B p-Value B p
Lumbar spine
Total BMD (g/cm2) −0.006 0.736 0.004 0
Z-score −0.122 0.451 −0.050 0
T-score −0.068 0.668 0.049 0
Femur
Total BMD (g/cm2) −0.027 0.111 0.002 0
Z-score −0.207 0.100 −0.025 0
T-score −0.178 0.159 0.004 0
The B represents the regression coefﬁcients of the multilevel regression analyses.
S vs. C: siblings vs. controls; P vs. C: patients vs. controls; P vs. S: patients vs. siblings.
c Statistical signiﬁcance not upheld after Simes correction.BMD: B=−0.113, 95% CI: −0.220 to −0.006, p=0.041; Z-score:
B=−1.109, 95% CI: −2.243 to 0.025, p=0.054; T-score: B=−1.199,
95% CI: −2.236 to −0.162, p=0.027). Results were not upheld after
Simes correction. No such association was found for the femur.
3.6. Exclusion of affective disorder and prolactin-raising AP
Repeating the analyses excluding siblings and controls with a history
of affective disorder did not affect the ﬁndings in the total group (n=
150), or in men (n=87), and thus remained negative. In women (n=
63), the signiﬁcance level of the negative association between group (pa-
tients) and femoral BMD was enhanced (see effect sizes and p-values in
Fig. 1). These ﬁndings held after Simes correction (pSimes: pb0.017).
In addition, a negative association in the lumbar spine became
apparent in the patient versus control comparison, although this was
not upheld after Simes correction (patients versus controls, total BMD:
B=−0.079, 95% CI:−0.171 to 0.013, p=0.093; Z-score: B=−0.888,
95% CI −1.756 to−0.021, p=0.045; T-score: B=−0.839, 95% CI
−1.672 to −0.005, p=0.049). Female siblings were not signiﬁcantly
different from female controls or patients for all BMD measures.
Analyses were once again repeated after excluding the six female
patients who used a prolactin-raising AP. Ten female patients remained
in the sample. Femoral BMD remained decreased in patients compared
to siblings at a trend-level of signiﬁcance (total BMD: B=−0.085, 95%
CI −0.171 to 0.000, p=0.051; Z-score: B=−0.748, 95% CI −1.484
to −0.011, p=0.047; T-score: B=−0.708, 95% CI −1.437 to 0.021,
p=0.057), although effect sizes decreased with 23%, 24% and 26% re-
spectively. The reduction in BMD in patients compared to controls
was no longer signiﬁcant (total BMD: B=−0.073, 95% CI: −0.152 toP vs. C P vs. S
-Value B p-Value B p-Value
.872 −0.013 0.693 −0.017 0.552
.842 −0.253 0.414 −0.203 0.456
.841 −0.151 0.617 −0.201 0.452
.927 −0.058 0.070 −0.061 0.033c
.897 −0.439 0.067 −0.414 0.050
.985 −0.380 0.114 −0.384 0.069
Table 4




S vs. C P vs. C P vs. S S vs. C P vs. C P vs. S
χ2 p-Value B p-Value B p-Value B p-Value B p-Value B p-Value Β p-Value
Lumbar spine
Total BMD 1.01 0.603 0.010 0.831 0.009 0.868 −0.001 0.973 0.006 0.836 −0.057 0.204 −0.064 0.167
Z-score 1.01 0.604 0.069 0.878 −0.025 0.961 −0.094 0.814 −0.069 0.811 −0.706 0.098 −0.637 0.143
T-score 1.16 0.561 0.137 0.757 0.081 0.870 −0.056 0.885 0.047 0.868 −0.639 0.124 −0.686 0.105
Femur
Total BMD 0.08 0.961 −0.005 0.918 −0.065 0.231 −0.060 0.162 0.005 0.863 −0.100 0.010c −0.104 0.008c
Z-score 0.10 0.952 −0.061 0.855 −0.384 0.303 −0.323 0.273 −0.015 0.948 −0.884 0.009d −0.869 0.011c
T-score 0.09 0.955 −0.009 0.979 −0.285 0.446 −0.276 0.350 −0.004 0.986 −0.851 0.012c −0.847 0.015c
Total BMD in gram per cm2.
The B represents the regression coefﬁcients of the multilevel regression analyses.
S vs. C: siblings vs. controls; P vs. C: patients vs. controls; P vs. S: patients vs. siblings.
c Statistical signiﬁcance remains after Simes correction.
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0.071; T-score: B=−0.592, 95% CI −1.268 to 0.084, p=0.086), as
effect sizes decreased with respectively 31%, 32% and 34% (Fig. 1).
4. Discussion
This study examined BMD as a potential biological marker of cu-
mulative endogenous estrogen exposure in patients with a psychotic
disorder, non-psychotic siblings of patients with a psychotic disorder
and controls. In the entire sample, group was not conclusively associ-
ated with BMD outcome measures, however BMD was directionally
lower in patients compared to controls and siblings. Signiﬁcantly de-
creased BMD was found speciﬁcally in the femur of female patients.
After exclusion of patients with prolactin-raising AP, the reduction
in femoral BMD was attenuated.
4.1. Findings
4.1.1. Total group (men and women)
Contrary to the initial hypothesis, individuals at higher than aver-
age and highest genetic risk for psychotic disorder did not have sig-
niﬁcantly decreased BMD measures compared to controls. Although
patients showed consistently lower BMD measures than controls
and siblings, the associations were statistically inconclusive or


























Total BMD; AD (-)
Total BMD; AD (-), PRL-raising AP (-)
Z-score; AD (-)
Z-score; AD (-), PRL-raising AP (-)
T-score; AD (-)
T-score; AD (-), PRL-raising AP (-)
Fig. 1. Modeled effects of genetic risk of psychotic disorder (group) on femoral BMD in wo
disorder among controls and siblings; PRL-raising AP (−): exclusion of prolactin-raising APindicative of reduced BMD in schizophrenia, some (Howes et al.,
2005) did not ﬁnd a signiﬁcant reduction in BMD in patients with
schizophrenia.
Siblings were not statistically different from controls, indicating
that reduced cumulative endogenous estrogen exposure is not a
marker of shared familial risk for psychotic disorder.4.1.2. Sex-speciﬁc ﬁndings
All BMD measures in the femurs of female patients were signiﬁ-
cantly lower than female controls and siblings. This is in accordance
with earlier ﬁndings that identiﬁed women with schizophrenia as a
population that is vulnerable for reduced BMD (Meaney and
O'Keane, 2007). However, the reduction in femoral BMDwas less pro-
nounced and with reduced signiﬁcance levels (up to p=0.086) after
excluding patients with prolactin-raising AP, suggesting a negative
effect of prolactin-raising AP on BMD or lack of power (see below).
In addition, there was no main effect of prolactin-raising AP on femo-
ral BMD, whereas such an effect was apparent for lumbar BMD.
A population-based study concluded that schizophrenia may be an
independent determinant of poor skeletal status in women, after
adjusting for AP use (among other factors) (Partti et al., 2010). Maric
et al. (2005) examined BMD in the lumbar spine of 19 female patients
presentingwith a ﬁrst episode of psychosis and healthy female controls.
They found that patients had amassed signiﬁcantly less bonemass than
healthy controls. The femur was not examined in this study. In theirPatients
P vs. C: p=0.006c; P vs. S: p=0.00 6c
P vs. C: p=0.005c; P vs. S: p=0.005c
P vs. C: p=0.072; P vs. S: p=0.051
P vs. C: p=0.006c; P vs. S: p=0.007c
P vs. C: p=0.086; P vs. S: p=0.057
P vs. C: p=0.071; P vs. S: p=0.047
men. B's are compared to controls represented as zero. AD (−): exclusion of affective
s. cStatistical signiﬁcance remains after Simes correction.
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secondary to the disease status of psychotic disorder are likely less
prominent in individuals presenting with a ﬁrst episode of psychosis.
Our ﬁndings in 16 female patients also indicated a reduction in BMD
in the femur aswell as in the lumbar spine (only after exclusion of affec-
tive disorder). Thus, similar toMaric et al. (2005), we cautiously suggest
that, to the degree that BMD is a biologicalmarker of cumulative endog-
enous estrogen exposure, reduced BMD may reﬂect diminished
estrogen-induced neuroprotection and synaptic plasticity which, in
turn, may place women at risk of developing a psychotic disorder.
However, since this risk was not shared with siblings, it likely reﬂects
a unique environmental experience associatedwith lifestyle, exogenous
exposures or stochastic mechanisms. Nevertheless, if a primary role
for estrogen exists, the ﬁndings indicate that it does not exclude an
additional effect of prolactin-raising APs on BMD (see below under
Antipsychotic medication).
In contrast to our ﬁndings in women, no association between psy-
chotic disorder and BMDwas revealed in men. Theoretically, the effects
of estrogen on both brain and bone are not speciﬁc to women: andro-
gens are aromatized focally and reach biologically effective concentra-
tions at these tissue sites in men (Boerma et al., 2010). In support of
this, beneﬁcial effects of estrogen and its receptor modulators as
adjunctive therapy for psychosis have been reported in both sexes
(Kulkarni et al., 2008, 2010, 2011). However, in men, the availability
of endogenous estrogen is entirely dependent on aromatase. Possibly,
the expression and/or activity of aromatase in the brain is altered in dis-
ease states (Melcangi et al., 2011). For example, if psychotic disorder
should lead to altered function of aromatase speciﬁcally in the male
brain (but not in bone), cerebral estrogen levels will be low while
BMD remains unaffected. If this were true, the use of BMD as an indirect
marker of cerebral estrogen exposure would not be informative. In
women, neuroprotective effects of estrogen may be enhanced by cyclic
availability of endogenous progesterone (Azcoitia et al., 2011). Due to
dysmenorrhea, women with psychotic disorder may not beneﬁt from
the synergy of both hormones, thereby enlarging the difference
between groups. This lends plausibility to the hypothesis that sex-
speciﬁc (patho)physiological mechanisms related to the disease state
may operate.
An alternative explanation for our inconclusive ﬁndings in men
may be found in the sample characteristics. The mean BMD measures
of 13 male controls were rather low. Z-scores in the control group
were expected to be approximately zero, as this represents the
mean in the general population (corrected for sex, age and ethnicity).
However, in the present sample, the mean lumbar Z-score was nega-
tive in male controls. In addition, all mean BMD measures of both the
lumbar spine and the femur were lower in male controls than in male
siblings. This may have potentially masked a true association in men
and in the total group.
4.1.3. Antipsychotic medication
A signiﬁcant association between prolactin-raising AP and BMD
was found in women, but not in men. More speciﬁcally, the current
use of a prolactin-raising AP was negatively associated with BMD in
the lumbar spine of female patients (though not after Simes correc-
tion). This is of interest, as our ﬁndings of reduced BMD in female
patients were present in the femur, but not the lumbar spine. In the
literature, there is a large body of work reporting signiﬁcant negative
associations between ﬁrst-generation AP and BMD (Bilici et al., 2002;
Meaney et al., 2004; Howard et al., 2007; Kishimoto et al., 2008).
Conversely, several other studies failed to discover an association be-
tween BMD and APs (Howes et al., 2005; Hummer et al., 2005; Lee
et al., 2010; Renn et al., 2010). Women have been described as partic-
ularly prone to AP-induced hyperprolactinemia (Smith et al., 2002;
Kinon et al., 2003), although the biological substrate remains unclear.
Pharmacokinetic factors, such as a higher proportion of body fat and
increased cerebral blood ﬂow that have been proposed to underliethe better treatment response to AP in women (Kolsch and Rao,
2002), may operate. Because there was a loss of effect size and statis-
tical signiﬁcance when women with prolactin-raising AP were
excluded, we cannot exclude the possibility of a sex-speciﬁc suscepti-
bility to AP-induced hyperprolactinemia in women as partial expla-
nation for the ﬁndings. At the same time, this analysis resulted in a
37.5% reduction in sample size and thus low statistical power to de-
tect BMD differences at conventional alpha-level. A meta-analysis of
the effects of AP on BMD has not been published but is warranted,
considering the contradictory results in this clinically important
matter.
4.2. Methodological considerations
The sample size was not particularly large. A group×sex interac-
tion was possibly not found due to an unbalanced sex distribution
over the relatively small groups in combination with low mean BMD
values in male controls. Thus, whether tests for interaction lacked
power because of the small proportion of males in the control group,
or whether there is simply no effect of group conditional on gender,
remains to be elucidated in future studies. Nevertheless, all results
from models restricted to the female part of the sample were upheld
after Simes correction (Fig. 1 and Table 4), with the exception of the
repeated analyses in the smallest subgroup (exclusion of both siblings
and controls with a history of affective disorder and patients with a
prolactin-raising AP). It is debatable whether correction for multiple
testing is appropriate in the present study. Six out of eighteen compar-
isons in women rendered signiﬁcant ﬁndings. Given that the probabil-
ity of a type I error is only 5%, the number of positive ﬁndingsmarkedly
exceeds the number of false-positive ﬁndings that would have been
expected by chance alone. In summary, lack of power does not preclude
detection of positive ﬁndings, as shown in the present study, but the
inconclusive ﬁndings need replication in a larger population, before
deﬁnite conclusions can be reached.
Although BMD is an indirect measure of endogenous estrogen ex-
posure, a clear advantage of BMD is that it reﬂects cumulative lifetime
exposure, while the direct measurement of estrogen in serum or urine
is a momentary assessment of estrogen levels. The latter would have
been less informative regarding the research question under study.
Nevertheless, hormone levels associated with the hypothalamus–
pituitary–gonadal axis could have aided in excluding (peri)meno-
pausal state in female patients, although subjective reports were neg-
ative and, in combination with the age range (17–43 years), it is
unlikely that our ﬁndings, in whole or in part, can be ascribed to loss
of BMD secondary to menopause. Moreover, analyses were adjusted
for menstrual irregularities.
The present sample is representative of the total (patient) popula-
tion in our area, and confounders were corrected for. With regard to
substance abuse, analyses were adjusted for the a priori hypothesized
confounders of alcohol, tobacco and cannabis use. There is little
evidence for an association between other (non-cannabis) drugs and
BMD. In our data, there was no signiﬁcant main effect of other drugs
on BMD. In addition, adjustment for other drug use did not affect the
pattern of the ﬁndings (results available upon request). Although best
estimates of sunlight exposure were quantiﬁed, measurement of vita-
min D blood levels could have been a useful alternative. In addition,
serum prolactin would be a valuable objective measure. Unfortunately,
these blood sample measures were not available.
The majority of publications to date focused primarily on the
effects of prolactin-raising antipsychotics on BMD. To the best of our
knowledge, this is the ﬁrst study to investigate associations between
different levels of familial risk of psychotic disorder and BMD.
Naturally, cross-sectional analyses cannot identify causal relation-
ships. Over the follow-up, all participants have undergone a second
DEXA scan. The disease course in patients and the possible transition
of healthy siblings to patient status may provide further clues to the
31C. van der Leeuw et al. / Schizophrenia Research 143 (2013) 25–31potential role of estrogen in the etiology and pathophysiology of
psychotic disorders.
4.3. Conclusions
There was no evidence for low cumulative endogenous estrogen
exposure (asmeasured by BMD), as an endophenotypicmarker for psy-
chotic disorder. BMD reduction was associated with being female and
patient, suggesting that unique environmental factors contributing to
primary low estrogen levels in women may impact the risk of develop-
ing a psychotic disorder, in support of the estrogen hypothesis of
schizophrenia. However, gender-speciﬁc susceptibility to the effects of
prolactin-raising AP on BMD may also operate.
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